Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 34, Issue 3, 2016, Pages 466-472

  Ruiz Irastorza, Guillermo ^a,j   Garcia, Miriam ^a   Espinosa, Gerard ^b   Cabezas Rodríguez, Ivan ^c   Mitjavila, Francesca ^d   González León, Rocío ^e   Sopeña, Bernardo ^f   Perales, Isabel ^g   Pinilla, Blanca ^h   Rodríguez Carballeira, Mónica ^d   López Dupla, Jesús Miguel ⁱ   Callejas, Jose Luis ^j   Castro, Antonio ^k   Tolosa, Carles ^l   Sánchez García, María Esther ^m   Pérez Conesa, Mercedes ⁿ   Navarrete Navarrete, Nuria ^o   Rodríguez, Ana Paula ^p   Herranz, María Teresa ^q,v   Pallarés, Lucio ^r   Akasbi, M ^s   Callejas, J L ^j   Caminal, L ^c   Canora, J ^t   Carrasco, N ^u   Castillo, M J ^e   Castro, A ^k   Chamorro, A J ^x   Erdozain, J G ^y   Espinosa, G ^u   Fonseca, E M ^z   Frutos, B ^t   Garcia M ^a   Garcia Morales M ^b   Garcia Sanchez A I ^s   Gil, A ^aa   Gonzalez Leon R ^e   Hurtado, R ^w   Jimenez Alonso J F ^o   Lopez Dupla J M ⁱ   Martin alvarez H ^g   Mico M L ^b   Mitjavila, F ^d   Navarrete, N ^o   Nunez Cuerda E ^g   Pallares L ^r   Parra, S ^k   Perales, I ^t   Perez Conesa M ⁿ   Pinilla, B ^t   Rodriguez A P ^p   Rodriguez Carballeira M ^d   Saez L ^b   Salvador, G ^u   Sanchez Garcia E ^m   Serralta, G ^ab   Tolosa, C ^l   Villalba, M V ^h   more..

^a BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^g HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^j HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^k HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^l Servicio de Oncología Médica   (Spain)

^m HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^o HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^p Galician Health System   (Spain)

^q HOSPITAL MORALES MESEGUER   (Spain)

^r HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^s HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^t HOSPITAL DE MENDARO   (Spain)

^u HOSPITAL DE CABUEÑES   (Spain)

^v HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^w HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^x HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^y HOSPITAL UNIVERSITARIO LA FE   (Spain)

^z Nuestra Senõra del Prado General Hospital   (Spain)

^aa Hospital de Manises   (Spain)

^ab HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

more..

Author keywords

Damage; Glucocorticoids; Hydroxychloroquine; Immunosuppressive drugs; Lupus activity; Lupus nephritis; Systemic lupus erythematosus; Therapy; Vitamin D

Indexed keywords

AZATHIOPRINE; CALCIUM; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; VITAMIN D;

ADULT; ARTICLE; CALCIUM INTAKE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SLEDAI; SPAIN; SPANIARD; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN INTAKE; CLINICAL PRACTICE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; PATIENT ACUITY; STATISTICS AND NUMERICAL DATA; SYMPTOM ASSESSMENT;

ADULT; CALCIUM; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; PATIENT ACUITY; PRACTICE PATTERNS, PHYSICIANS'; PREDNISONE; SPAIN; SYMPTOM ASSESSMENT; VITAMIN D;

EID: 84982830473     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. van VOLLENHOVEN RF, MOSCA M, BERTSIAS G et al.: Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73: 958-67.
2. BERTSIAS GK, TEKTONIDOU M, AMOURA Z et al.: Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-82.
3. HAHN BH, McMAHON MA, WILKINSON A et al.: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
4. RUIZ-IRASTORZA G, ESPINOSA G, FRUTOS MA et al.: Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia 2012; 32 (Suppl. 1): 1-35.
5. GROSSMAN JM, GORDON R, RANGANATH VK et al.: American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515-26.
6. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 1997; 40: 1725.
7. BUTTGEREIT F, STRAUB RH, WEHLING M, BURMESTER GR: Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004; 50: 3408-17.
8. GLADMAN DD, IBAñEZ D, UROWITZ MB: SLE Disease Activity Index 2000. J Rheumatol 2002; 29: 288-91.
9. ALARCóN GS, FRIEDMAN AW, STRAATON KV et al.: Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus 1999; 8: 197-209.
10. UROWITZ MB, GLADMAN DD, TOM BDM, IBAñEZ D, FAREWELL VT: Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 2152-8.
11. NOSSENT J, KISS E, ROZMAN B et al.: Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010; 19: 949-56.
12. PARKER B, UROWITZ MB, GLADMAN DD et al.: Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2014.
13. ZONANA-NACACH A, BARR SG, MAGDER LS, PETRI MA: Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-8.
14. ALBRECHT K, HUSCHER D, RICHTER J et al.: Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s. Lupus Sci Med 2014; 1: e000059.
15. BRUCE IN, O'KEEFFE AG, FAREWELL V et al.: Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2015; 74: 1706-13.
16. RUIZ-ARRUZA I, UGARTE A, CABEZAS-RODRIGUEZ I, MEDINA J-A, MORAN M-A, RUIZ-IRASTORZA G: Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2014; 53: 1470-6.
17. THAMER M, HERNáN MA, ZHANG Y, COTTER D, PETRI MA: Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009; 36: 560-4.
18. RUIZ-IRASTORZA G, RAMOS-CASALS M, BRITO-ZERON P, KHAMASHTA MA: Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-8.
19. PEGO-REIGOSA JM, COBO-IBáñEZ T, CALVOALéN J et al.: Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res 2013; 65: 1775-85.
20. PARKER BJ, BRUCE IN: High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 2007; 16: 387-93.
21. HOUSSIAU FA, VASCONCELOS C, D'CRUZ DP et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus highdose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31.
22. RUIZ-IRASTORZA G, DANZA A, PERALES I et al.: Prednisone in lupus nephritis: How much is enough? Autoimmun Rev 2014; 13: 206-14.
23. CONDON MB, ASHBY D, PEPPER RJ et al.: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72: 1280-6.
24. RUIZ-ARRUZA I, BARBOSA C, UGARTE A, RUIZ-IRASTORZA G: Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev 2015.
25. PEGO-REIGOSA JM, RUA-FIGUEROA I, LOPEZ-LONGO FJ et al.: Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. Lupus 2015; 24: 720-9.